Press coverage about Egalet Corporation (NASDAQ:EGLT) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Egalet Corporation earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news articles about the specialty pharmaceutical company an impact score of 45.3574239652582 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Egalet Corporation (EGLT) Scheduled to Post Earnings on Wednesday (americanbankingnews.com)
- Egalet Corporation (EGLT) Stock Price stands -11.82% away from 20 SMA – Voice Of Analysts (analystsbuzz.com)
- Egalet to Present at Upcoming Scientific and Investor Conferences (finance.yahoo.com)
- ETFs with exposure to Egalet Corp. : October 30, 2017 (finance.yahoo.com)
- Egalet Corporation (EGLT) Stock Technical Analysis – Wall Street Morning (wallstreetmorning.com)
A number of equities analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Egalet Corporation in a report on Sunday, August 20th. JMP Securities lowered their price target on Egalet Corporation from $15.00 to $6.00 and set a “market outperform” rating for the company in a report on Friday, July 14th. Guggenheim set a $7.00 price target on Egalet Corporation and gave the company a “buy” rating in a report on Monday, August 14th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $6.00 price target (down from $14.00) on shares of Egalet Corporation in a report on Thursday, August 10th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $7.10.
Egalet Corporation (NASDAQ EGLT) traded down 3.2143% during midday trading on Wednesday, hitting $0.9485. The stock had a trading volume of 433,998 shares. Egalet Corporation has a 12-month low of $0.92 and a 12-month high of $10.00. The company’s market cap is $24.91 million. The company has a 50-day moving average price of $1.23 and a 200-day moving average price of $1.94.
Egalet Corporation (NASDAQ:EGLT) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.10). The firm had revenue of $6.26 million during the quarter, compared to analyst estimates of $6.68 million. Egalet Corporation had a negative return on equity of 607.49% and a negative net margin of 444.50%. Egalet Corporation’s revenue was up 81.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.97) EPS. Equities analysts anticipate that Egalet Corporation will post ($2.75) EPS for the current year.
Egalet Corporation Company Profile
Egalet Corporation is a specialty pharmaceutical company. The Company is engaged in developing, manufacturing and commercializing treatments for pain and other conditions. The Company’s products include OXAYDO and SPRIX Nasal Spray. The Company is developing two late-stage product candidates, ARYMO ER and Egalet-002 using Guardian Technology.
What are top analysts saying about Egalet Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Egalet Corporation and related companies.